Windecker, S., Remondino, A., Eberli, F., Jüni, P., Räber, L., Wenaweser, P., Togni, M., Billinger, M., Tüller, D., Seiler, C., Roffi, M., Corti, R., Sütsch, G., Maier, W., Lüscher, T., Hess, O.M., Egger, M. and Meier, B. (2005) Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. The New England Journal of Medicine, 353, 653-662. doi:10.1056/NEJMoa051175

has been cited by the following article:

• TITLE: Major clinical and angiographic outcome of drug eluting stents in native ostial coronary artery disease

  AUTHORS: Khaled R. Abd El Meguid, Hesham B. Mahmoud, Fouad R. Amin, Jonathan R. Clague

  KEYWORDS: Bare Metal Stent; DRUG Eluting Stent; Ostial Coronary Lesions

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.3 No.3, June 20, 2013

  ABSTRACT: Objectives: The study was designed to evaluate the efficacy and safety of drug eluting stents (DESs) in aorto-ostial (A-O) coronary artery lesions, in terms of early and late restenosis rate; including clinical assessment, non-invasive stress testing and angiographic follow-up. Also, the study was aimed to compare the results of implantation of drug eluting stents (DES) to that of bare metal stents (BMS) in aortoostial lesions done over a previous 5 years in Royal Brompton Hospital. Background: The safety and effectiveness of DESs for the treatment of aortoostial lesions. Methods: We included 161 consecutive patients with symptoms subjective of angina pectoris or objective evidence of myocardial ischemia; who underwent percutaneous coronary interventions (PCI) in coronary ostial lesions using DES. The patients were divided into two groups based on the site of ostial lesion. The control group consisted of 125 consecutive patients who underwent percutaneous coronary intervention for ostial lesions using bare metal stents (BMS) implantation in the period immediately before the introduction of DES. The incidence of major adverse cardiac events (MACE), including death or Q-wave myocardial infarction (MI), need for repeated revascularization procedure CABG or angioplasty, were recorded in-hospital and at twelve months ± 3 months. Follow-up angiography was only performed in case of recurrent symptoms subjective of myocardial ischemia or if there was objective evidence of myocardial ischemia by stress testing. Results: The initial procedure was successful in 149 patients (92.5%) in the DES arm. There were no statistically significant major in-hospital complications in the DES group, compared to BMS group which showed 4 cases of in-hospital deaths (p = 0.017). At Twelve months ± 3 months follow-up, MACE were significantly less frequent in the DES group compared to the BMS group, including death (0.8% vs. 6.4%, p = 0.004) and need for CABG (1.7% vs. 10%, p = 0.012). Conclusions: The main finding of our study is that, compared to the BMS, implantation of the DES in coronary ostial lesions appears safe and effective. It is associated with high procedural success rate, low immediate and in-hospital complication rate, infrequent late adverse events and favourable long-term clinical and angiographic outcomes compared with bare metal stents implantation at 12-month follow-up. Advanced age, previous myocardial infarction and acute coronary syndromes at presentation were all found to be independent positive predictors for clinical events after drug eluting stent implantation in ostial lesions.